<DOC>
	<DOCNO>NCT01368276</DOCNO>
	<brief_summary>The purpose study learn safety risk use talimogene laherparepvec patient already receive treatment talimogene laherparepvec study 005/05 ( NCT00769704 ) , see extended treatment talimogene laherparepvec destroy melanoma tumor .</brief_summary>
	<brief_title>An Extended Use Study Safety Efficacy Talimogene Laherparepvec Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Previously participate protocol 005/05 ( NCT00769704 ) : 1. receive maximum number talimogene laherparepvec treatment injection cycle GMCSF allowable patient study 005/05 , 2. new injectable lesion ( ) appear previous resolution injectable disease study 005/05 . New injectable lesion must appear within ≤ 12 month End Treatment visit 005/05 study . 2 . In opinion investigator sponsor 's medical monitor treatment warrant [ e.g. , patient clinically relevant progressive disease ( PDr ) ] . 3 . Performance status ( Eastern Cooperative Oncology Group , ECOG ) 0 1 . 4 . For patient randomize talimogene laherparepvec : Injectable disease ( i.e . suitable direct injection use ultrasound guidance ) define least 1 injectable cutaneous , subcutaneous nodal melanoma lesion . There minimum size injection . 1 . Prior Common Terminology Criteria Adverse Events ( CTCAE ) grade 3 4 toxicity relate talimogene laherparepvec organ system ( exception injection site reaction , fever vomit ) . 2 . History Grade 3 fatigue last &gt; 1 week talimogene laherparepvec treatment . 3 . History Grade 3 arthralgia/myalgias talimogene laherparepvec treatment . 4 . History ≥ Grade 2 autoimmune reaction , allergic reaction urticaria talimogene laherparepvec related nonhematological toxicity talimogene laherparepvec treatment require dose delay discontinuation talimogene laherparepvec therapy . 5 . PDr participate study 005/05 6 . Patient request withdrawn study 005/05 unable comply demand 005/05 trial . 7 . At discretion investigator , patient withdrawn 005/05 trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Stage IIIb , IIIc IV Disease</keyword>
	<keyword>oncolytic</keyword>
	<keyword>OncoVex</keyword>
	<keyword>OncoVEX^GM-CSF</keyword>
</DOC>